Histidine-rich glycoprotein in thrombolytic therapy: has it clinical relevance?
The plasma concentrations of histidine-rich glycoprotein and plasminogen were measured and those of free plasminogen calculated in 34 patients with acute myocardial infarction treated with thrombolytic drugs. We investigated whether the plasma levels of histidine-rich glycoprotein and free plasminogen were associated with clinical parameters such as the occurrence and time of successful reperfusion, the incidence of reocclusion and the presence and extent of the systemic lytic state. The mean (+/- SD) pretreatment concentration of histidine-rich glycoprotein was 1.08 +/- 0.24 U/ml, which was almost identical with the normal reference values. After thrombolysis, the mean level decreased slightly. We found no support for a role of these proteins in achieving therapeutic success and only a faint suggestion that histidine-rich glycoprotein might contribute to reocclusion. Surprisingly, the non- or only limited occurrence of systemic lytic state appeared to be associated with a low level of histidine-rich glycoprotein, instead of the high level expected on theoretical grounds. It is therefore unlikely that histidine-rich glycoprotein is of clinical relevance for thrombolytic therapy of acute myocardial infarction.